145 related articles for article (PubMed ID: 10838497)
1. Relative expression of the RET9 and RET51 isoforms in human pheochromocytomas.
Le Hir H; Charlet-Berguerand N; Gimenez-Roqueplo A; Mannelli M; Plouin P; de Franciscis V; Thermes C
Oncology; 2000 May; 58(4):311-8. PubMed ID: 10838497
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.
Ramone T; Romei C; Ciampi R; Tacito A; Piaggi P; Torregrossa L; Ugolini C; Elisei R
Endocrine; 2019 Sep; 65(3):623-629. PubMed ID: 31278686
[TBL] [Abstract][Full Text] [Related]
3. The RET proto-oncogene in sporadic pheochromocytomas.
Takaya K; Yoshimasa T; Arai H; Tamura N; Miyamoto Y; Itoh H; Nakao K
Intern Med; 1996 Jun; 35(6):449-52. PubMed ID: 8835594
[TBL] [Abstract][Full Text] [Related]
4. High levels of tyrosine phosphorylated proto-ret in sporadic phenochromocytomas.
Le Hir H; Colucci-D'Amato LG; Charlet-Berguerand N; Plouin PF; Bertagna X; de Franciscis V; Thermes C
Cancer Res; 2000 Mar; 60(5):1365-70. PubMed ID: 10728700
[TBL] [Abstract][Full Text] [Related]
5. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
6. 5'-End RET splicing: absence of variants in normal tissues and intron retention in pheochromocytomas.
Le Hir H; Charlet-Berguerand N; de Franciscis V; Thermes C
Oncology; 2002; 63(1):84-91. PubMed ID: 12187076
[TBL] [Abstract][Full Text] [Related]
7. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
[TBL] [Abstract][Full Text] [Related]
8. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.
Rossel M; Pasini A; Chappuis S; Geneste O; Fournier L; Schuffenecker I; Takahashi M; van Grunsven LA; Urdiales JL; Rudkin BB; Lenoir GM; Billaud M
Oncogene; 1997 Jan; 14(3):265-75. PubMed ID: 9018112
[TBL] [Abstract][Full Text] [Related]
9. Absence of mutations at codon 768 of the RET proto-oncogene in sporadic and hereditary pheochromocytomas.
Yoshimoto K; Kimura T; Tanaka C; Moritani M; Iwahana H; Itakura M
Endocr J; 1996 Feb; 43(1):109-14. PubMed ID: 8732460
[TBL] [Abstract][Full Text] [Related]
10. Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase.
Scott RP; Eketjäll S; Aineskog H; Ibáñez CF
J Biol Chem; 2005 Apr; 280(14):13442-9. PubMed ID: 15677445
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
12. Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis.
de Graaff E; Srinivas S; Kilkenny C; D'Agati V; Mankoo BS; Costantini F; Pachnis V
Genes Dev; 2001 Sep; 15(18):2433-44. PubMed ID: 11562352
[TBL] [Abstract][Full Text] [Related]
13. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation.
Nilsson O; Tisell LE; Jansson S; Ahlman H; Gimm O; Eng C
JAMA; 1999 May; 281(17):1587-8. PubMed ID: 10235148
[No Abstract] [Full Text] [Related]
14. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2.
Ponder BA
Cancer Surv; 1995; 25():195-205. PubMed ID: 8718519
[No Abstract] [Full Text] [Related]
15. Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas.
Huang SC; Koch CA; Vortmeyer AO; Pack SD; Lichtenauer UD; Mannan P; Lubensky IA; Chrousos GP; Gagel RF; Pacak K; Zhuang Z
Cancer Res; 2000 Nov; 60(22):6223-6. PubMed ID: 11103773
[TBL] [Abstract][Full Text] [Related]
16. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the RET protooncogene in sporadic pheochromocytomas.
Lindor NM; Honchel R; Khosla S; Thibodeau SN
J Clin Endocrinol Metab; 1995 Feb; 80(2):627-9. PubMed ID: 7852530
[TBL] [Abstract][Full Text] [Related]
18. A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene.
Tessitore A; Sinisi AA; Pasquali D; Cardone M; Vitale D; Bellastella A; Colantuoni V
J Clin Endocrinol Metab; 1999 Oct; 84(10):3522-7. PubMed ID: 10522989
[TBL] [Abstract][Full Text] [Related]
19. Conservation of RET proto-oncogene splicing variants and implications for RET isoform function.
Carter MT; Yome JL; Marcil MN; Martin CA; Vanhorne JB; Mulligan LM
Cytogenet Cell Genet; 2001; 95(3-4):169-76. PubMed ID: 12063395
[TBL] [Abstract][Full Text] [Related]
20. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II.
Neumann HP; Eng C; Mulligan LM; Glavac D; Zäuner I; Ponder BA; Crossey PA; Maher ER; Brauch H
JAMA; 1995 Oct; 274(14):1149-51. PubMed ID: 7563486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
